Related references
Note: Only part of the references are listed.Antidiabetic Drug Voglibose Is Protective Against Ischemia-Reperfusion Injury Through Glucagon-Like Peptide 1 Receptors and the Phosphoinositide 3-Kinase-Akt-Endothelial Nitric Oxide Synthase Pathway in Rabbits
Masamitsu Iwasa et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2010)
GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats
Tohru Hira et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
David J. Grieve et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Chronic Administration of Voglibose, an alpha-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice
Yusuke Moritoh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart
Alvilde Ossum et al.
PHARMACOLOGICAL RESEARCH (2009)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects
Masayuki Arakawa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
David P. Sonne et al.
REGULATORY PEPTIDES (2008)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
An α-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients
Noriko Satoh et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion
DJ Hausenloy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart
NY Wang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Circulation and degradation of GIP and GLP-1
CF Deacon
HORMONE AND METABOLIC RESEARCH (2004)
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
M Kavianipour et al.
PEPTIDES (2003)
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics
A Lee et al.
DIABETES OBESITY & METABOLISM (2002)
Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat
E Bojanowska et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Share Paper
